FDA Sounds Positive On Bluebird’s One Gene Therapy But Doubts Another
The FDA signaled in briefing documents released that it may approve Bluebird bio Inc’s (NASDAQ:BLUE) beti-cel gene therapy to treat β-thalassemia for those…
Looking Into bluebird bio’s Return On Capital Employed
According to Benzinga Pro data, during Q1, bluebird bio (NASDAQ:BLUE) posted sales of $1.95 million. Earnings were up 21.22%, but bluebird bio still reported an overall loss of $122.15 million.
Stocks That Hit 52-Week Lows On Thursday
During the Thursday's session, 100 stocks hit new 52-week lows.
Attention Biotech Investors: Mark Your Calendar For These June PDUFA Dates
May turned out to be a month of mixed fortunes as far as regulatory reviews are concerned. New molecular entity approvals, an indicator of innovation in drug research, totaled three during the month, bringing the total for the year to 15. This compares to the 24 NMEs the Food and Drug Administration approved by May 2021.
Goldman Sachs Maintains Sell on bluebird bio, Lowers Price Target to $2
Goldman Sachs maintains bluebird bio (NASDAQ:BLUE) with a Sell and lowers the price target from $3 to $2.
Why This Analyst Has ‘Little Conviction’ On CRISPR’s Upcoming Trial Data
RBC Capital Markets says it remains on the sidelines given commercial uptake for CRISPR Therapeutics’ (NASDAQ: CRSP) sickle cell disease (SCD)/beta-thalassemia…
Analyst Ratings for bluebird bio
Over the past 3 months, 6 analysts have published their opinion on bluebird bio (NASDAQ:BLUE) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.
55 Stocks Moving In Friday’s Mid-Day Session
Gainers
Swvl Holdings Corp. (NASDAQ: SWVL) surged 24.4% to $7.50. Swvl Holdings 13D Filing from investor Ahmed Sabbah showed a new 6.4% stake in the company.
